Using dual anti-CTLA-4/anti-PD-1 inhibitors and a DNA vaccine in mouse melanoma could increase the infiltration of CD8+ T cells into the tumour.99 Currently, several clinical trials evaluating mRNA cancer vaccines are being conducted in combination with immune checkpoint inhibitors (NCT03633110, supplementary Table 2). Here, CTLA4 is linked to neoplasm.